444 related articles for article (PubMed ID: 20655966)
1. Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Luo Y; Ling Y; Guo W; Pang J; Liu W; Fang Y; Wen X; Wei K; Gao X
J Control Release; 2010 Oct; 147(2):278-88. PubMed ID: 20655966
[TBL] [Abstract][Full Text] [Related]
2. Actively targeted cetuximab conjugated gamma-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells.
Maya S; Sarmento B; Lakshmanan VK; Menon D; Jayakumar R
J Biomed Nanotechnol; 2014 Aug; 10(8):1416-28. PubMed ID: 25016642
[TBL] [Abstract][Full Text] [Related]
3. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis.
Aranha O; Grignon R; Fernandes N; McDonnell TJ; Wood DP; Sarkar FH
Int J Oncol; 2003 Apr; 22(4):787-94. PubMed ID: 12632069
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel-induced apoptosis in melanoma cells is dependent on activation of caspase-2.
Mhaidat NM; Wang Y; Kiejda KA; Zhang XD; Hersey P
Mol Cancer Ther; 2007 Feb; 6(2):752-61. PubMed ID: 17308071
[TBL] [Abstract][Full Text] [Related]
5. Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells.
Fabbri F; Amadori D; Carloni S; Brigliadori G; Tesei A; Ulivi P; Rosetti M; Vannini I; Arienti C; Zoli W; Silvestrini R
J Cell Physiol; 2008 Nov; 217(2):494-501. PubMed ID: 18615564
[TBL] [Abstract][Full Text] [Related]
6. Adenosine induces cell-cycle arrest and apoptosis in androgen-dependent and -independent prostate cancer cell lines, LNcap-FGC-10, DU-145, and PC3.
Aghaei M; Karami-Tehrani F; Panjehpour M; Salami S; Fallahian F
Prostate; 2012 Mar; 72(4):361-75. PubMed ID: 21656837
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.
Mediavilla-Varela M; Pacheco FJ; Almaguel F; Perez J; Sahakian E; Daniels TR; Leoh LS; Padilla A; Wall NR; Lilly MB; De Leon M; Casiano CA
Mol Cancer; 2009 Aug; 8():68. PubMed ID: 19715609
[TBL] [Abstract][Full Text] [Related]
8. Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway.
Shaikh IA; Brown I; Schofield AC; Wahle KW; Heys SD
Prostate; 2008 Nov; 68(15):1635-46. PubMed ID: 18668525
[TBL] [Abstract][Full Text] [Related]
9. A novel hydroxamic acid compound, BMD188, demonstrates anti-prostate cancer effects by inducing apoptosis. I: In vitro studies.
Li L; Zhu Z; Joshi B; Porter AT; Tang DG
Anticancer Res; 1999; 19(1A):51-60. PubMed ID: 10226524
[TBL] [Abstract][Full Text] [Related]
10. PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Nagesh PKB; Johnson NR; Boya VKN; Chowdhury P; Othman SF; Khalilzad-Sharghi V; Hafeez BB; Ganju A; Khan S; Behrman SW; Zafar N; Chauhan SC; Jaggi M; Yallapu MM
Colloids Surf B Biointerfaces; 2016 Aug; 144():8-20. PubMed ID: 27058278
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
[TBL] [Abstract][Full Text] [Related]
12. Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer.
Zhang X; He Z; Xiang L; Li L; Zhang H; Lin F; Cao H
Drug Des Devel Ther; 2019; 13():1357-1372. PubMed ID: 31118572
[No Abstract] [Full Text] [Related]
13. Cellular cytotoxicity and in-vivo biodistribution of docetaxel poly(lactide-co-glycolide) nanoparticles.
Esmaeili F; Dinarvand R; Ghahremani MH; Ostad SN; Esmaily H; Atyabi F
Anticancer Drugs; 2010 Jan; 21(1):43-52. PubMed ID: 19809300
[TBL] [Abstract][Full Text] [Related]
14. Dual docetaxel/superparamagnetic iron oxide loaded nanoparticles for both targeting magnetic resonance imaging and cancer therapy.
Ling Y; Wei K; Luo Y; Gao X; Zhong S
Biomaterials; 2011 Oct; 32(29):7139-50. PubMed ID: 21726899
[TBL] [Abstract][Full Text] [Related]
15. Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Liu QJ; Xu XH; Shang DH; Tian Y; Lü WC; Zhang YH
Chin Med J (Engl); 2010 Feb; 123(3):356-60. PubMed ID: 20193259
[TBL] [Abstract][Full Text] [Related]
16. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel.
Liu D; Liu Z; Wang L; Zhang C; Zhang N
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):262-9. PubMed ID: 21435845
[TBL] [Abstract][Full Text] [Related]
17. In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
Ostacolo L; Marra M; Ungaro F; Zappavigna S; Maglio G; Quaglia F; Abbruzzese A; Caraglia M
J Control Release; 2010 Dec; 148(2):255-63. PubMed ID: 20816710
[TBL] [Abstract][Full Text] [Related]
18. Induction of apoptosis and cell cycle arrest by a chalcone panduratin A isolated from Kaempferia pandurata in androgen-independent human prostate cancer cells PC3 and DU145.
Yun JM; Kweon MH; Kwon H; Hwang JK; Mukhtar H
Carcinogenesis; 2006 Jul; 27(7):1454-64. PubMed ID: 16497706
[TBL] [Abstract][Full Text] [Related]
19. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
20. Emodin loaded solid lipid nanoparticles: preparation, characterization and antitumor activity studies.
Wang S; Chen T; Chen R; Hu Y; Chen M; Wang Y
Int J Pharm; 2012 Jul; 430(1-2):238-46. PubMed ID: 22465546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
